Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy
- PMID: 8760778
- DOI: 10.1016/s1081-1206(10)63498-9
Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy
Abstract
Background: Because ocular allergic disorders are important in terms of frequency and severity, there is a constant search for new topical antiallergic drugs. Nedocromil sodium has recently been introduced as a potential substitute for the mast cell stabilizer cromolyn sodium.
Objective: We compared the efficacy of topical 2% nedocromil sodium to that of 2% cromolyn sodium in treatment of the early-phase reaction of an experimental model of allergic conjunctivitis.
Methods: Guinea pigs were challenged topically with egg albumin 14 days after systemic immunization. Fifteen minutes before, immediately prior to, and 15 minutes after topical challenge, the animals received either 2% nedocromil sodium or 2% cromolyn sodium topically in one eye and phosphate buffered saline (PBS) in the other eye. Antigen-induced increase in vascular permeability was measured by the extravasation of intravenously injected Evans blue dye. Animals that were immunized and topically challenged but did not receive Evans blue were used for histologic studies.
Results: Evans blue extravasation from ocular tissues significantly decreased in drug-treated eyes compared with PBS-treated eyes (P < .01). Further, the cellular infiltrate (mast cells, eosinophils, and neutrophils) in the substantia propria of the conjunctiva was markedly reduced in the drug-treated eyes. No significant difference was observed between the nedocromil sodium- or cromolyn sodium-treated eyes.
Conclusions: Topical 2% nedocromil sodium reduces the early-phase reaction of the allergic response as effectively as 2% sodium cromoglycate in a guinea pig model of ocular anaphylaxis.
Similar articles
-
Pharmacologic modulation of vascular permeability in ocular allergy in the rat.Invest Ophthalmol Vis Sci. 1990 Jan;31(1):176-80. Invest Ophthalmol Vis Sci. 1990. PMID: 2105283
-
Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.Clin Ther. 2000 Dec;22(12):1462-72. doi: 10.1016/s0149-2918(00)83044-1. Clin Ther. 2000. PMID: 11192137 Clinical Trial.
-
Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis.Clin Exp Allergy. 1999 Apr;29(4):529-36. doi: 10.1046/j.1365-2222.1999.00501.x. Clin Exp Allergy. 1999. PMID: 10202368 Clinical Trial.
-
Treating severe eye allergy.Clin Exp Allergy. 1998 Dec;28 Suppl 6:44-8. doi: 10.1046/j.1365-2222.1998.0280s6044.x. Clin Exp Allergy. 1998. PMID: 9988435 Review.
-
Comparative therapeutic studies with Tilavist.Allergy. 1995;50(21 Suppl):23-9; discussion 34-8. doi: 10.1111/j.1398-9995.1995.tb04253.x. Allergy. 1995. PMID: 7785747 Review.
Cited by
-
Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.Ocul Surf. 2021 Jul;21:66-77. doi: 10.1016/j.jtos.2021.05.004. Epub 2021 May 15. Ocul Surf. 2021. PMID: 34000363 Free PMC article. Review.
-
Animal models of ocular allergy and their clinical correlations.Curr Allergy Asthma Rep. 2003 Jul;3(4):345-51. doi: 10.1007/s11882-003-0097-3. Curr Allergy Asthma Rep. 2003. PMID: 12791214 Review.
-
Ocular mast cells. Characterization in normal and disease states.Clin Rev Allergy Immunol. 2001 Apr;20(2):243-68. doi: 10.1385/CRIAI:20:2:243. Clin Rev Allergy Immunol. 2001. PMID: 11349612 Review. No abstract available.
-
Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model.Graefes Arch Clin Exp Ophthalmol. 2017 Dec;255(12):2357-2362. doi: 10.1007/s00417-017-3781-z. Epub 2017 Aug 24. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28840310